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Abstract 
 
Cell cycle progression in response to serum growth factors is dependent on the 
expression of functional Hdm2 (Mdm2), which  inhibits p53-dependent transcription 
of anti-proliferative genes. In a well characterised non-transformed human fibroblast 
model, growth factors induce the expression of Hdm2 with rapid kinetics. Here we 
dissect the mechanistic basis for this critical response. In contrast to previous studies 
in which components of the growth factor signalling pathways were over-expressed, 
hdm2 mRNA expression is not induced with immediate-early kinetics in these cells.  
Rather, the elevated Hdm2 protein levels which follow growth factor stimulation are 
primarily a consequence of PI3 kinase-dependent stabilisation of the Hdm2 protein 
combined with a global increase in protein synthesis.  
 
  
 
1. Introduction 
 
The transcription factor p53, acts at a pivotal point of multiple stress-response 
pathways, and as such its activity in proliferating cells must be tightly regulated in 
order to prevent activation of a cell-cycle arrest or apoptotic response. The primary 
pathway whereby p53 function is restricted in unstressed cells is via interaction with 
the Hdm2 oncoprotein (Mdm2 in mouse) [1]. Hdm2 suppresses the transcriptional 
activation function of p53, and also promotes its nuclear export and proteosome-
dependent destruction [2]. In absence of Hdm2 function, normal  fibroblast cells 
induce expression of the cdk inhibitor, p21WAF1,  and undergo a p53-dependent cell 
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cycle arrest [3], whereas in other cell-types, spontaneous apoptosis may occur [4-6]. 
Hdm2 / Mdm2 is itself a transcriptional target of p53, as the gene has a promoter, P2, 
which contains p53 binding sites [7,8] and, in in vitro cultured mouse embryo 
fibroblasts the levels of the mdm2-P2 mRNA transcript  is highly dependent upon p53 
[9]. A second promoter, P1, is constitutively active, though the mdm2 / hdm2-P1 
mRNA transcript is poorly translated [10].  
 
Levels of Hdm2 / Mdm2 protein are positively regulated by growth factor signalling 
pathways that promote cell proliferation and survival [11,12]. Several distinct 
mechanisms underlying this regulation have been demonstrated: Mosner et al [11] 
showed that the increased Mdm2 occurred in the absence of any increase in total 
mdm2 mRNA on Northern blots, however expression of the mdm2 gene was 
subsequently shown to be induced with immediate early kinetics in response to 
signalling from chimeric platelet-derived growth factor β receptors [13]. Experimental 
activation of one of the major growth factor receptor tyrosine kinase-induced 
pathways, the Ras-Raf-MEK-ERK kinase cascade, induces mdm2 P2-transcription 
through activation of AP1 and ETS transcription factor binding to sites in the murine 
P2-promoter [14]. We have previously shown that this pathway is at least partially 
conserved in human cells [15,16], and  Ras-Raf-MEK-ERK signalling also selectively 
promotes the export of hdm2 mRNA from the nucleus to sites of translation in the 
cytoplasm [16]. Ras-Raf-MEK-ERK signalling is also known to regulate Hdm2 
function through the increased transcription of the Hdm2-binding protein p14ARF [17]. 
Finally, growth factor induced activation of phosphatidylinositol-3 kinase (PI3 kinase) 
- Akt/PKB kinase signalling results in phosphorylation of Hdm2 / Mdm2, which 
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increases the levels of the protein by reducing its rate of proteosome-dependent 
degradation [18-20].  
 
Given that these mechanisms have been the subject of independent studies, it is 
difficult to determine their relative contribution to the levels in Hdm2 protein 
expression in any given situation. To address this, we have taken a well defined 
experimental model, induction of Hdm2 expression immediately following serum re-
stimulation of non-transformed human fibroblasts, and undertaken an investigation of 
the mechanisms regulating Hdm2 protein levels in these cells. 
 
2. Methods 
 
2.1. Cell culture, reagents, and cell cycle analysis 
MRC-5 hTERT cells  [21] were cultured in Dulbecco’s modified Eagle’s medium 
(Invitrogen) supplemented with 0.1% or 10% foetal calf serum (FCS) (Autogen 
Bioclear). The following chemicals were added where indicated: Nutlin-3 (Alexis 
Biochemicals), MG132 (Sigma), cyclohexamide (Sigma), LY294002 (Calbiochem), 
U0126 (Promega). For DNA content analysis, cells were fixed in 70% ethanol in PBS 
before DNA was stained with propidium iodide, and quantified using a FACSCalibur 
flow cytometer (BD Biosciences). Cells were transfected using Lipofectamine 2000 
reagent (Invitrogen).  
 
2.2. mRNA and protein quantification. 
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Western blotting was performed as described previously [16] using antibodies to 
Hdm2 (2A9 or 2A10 [22], (2A9 was used unless indicated otherwise)), p53 (DO-1, 
Serotec), p21WAF-1 (Clone SX118, Pharmingen), β-actin (Sigma), AKT, phospho-Ser- 
473 Akt, ERK1/ERK2 and phospho-Thr202r/Tyr204 ERK1/ERK2 (all from Cell 
Signalling Technology). mRNA analysis, cell fractionation, polyribosome 
purification, RNA extraction, and validation of the fractionation by semi-quantitative 
PCR for small cytoplasmic RNA Y4, was performed as described previously [16]. 
cDNA synthesis and Taqman quantitative PCR (qPCR) for hdm2-P1, hdm2-P2, 
hdm2-CDS and gapdh was performed using previously described primers and probes 
[16]. hdm2 qPCR assays were performed in duplicate, and mean values normalised to 
gapdh levels. n values represent the number of individually treated sets of cells 
analysed.  
 
3. Results  
 
3.1. Hdm2 is required for cell-cycle progression in hTERT-immortalised normal 
human fibroblasts. 
 
MRC-5 hTERT is an immortal cell line that has been derived by retroviral 
transduction of MRC-5, a well characterised human fibroblast strain, with a vector 
expressing the hTERT component of telomerase [21]. Previous work has shown that 
serum stimulation of growth arrested MRC-5 cells induces a rapid, and robust 
accumulation of Hdm2 protein [19]. We therefore first established whether MRC-5 
hTERT cells retain normal dependence upon serum growth factors and Hdm2 
function for cell cycle progression.  Culture of sub-confluent MRC-5 hTERT cells for 
  Regulation of Hdm2 expression 
- 6 - 
24 h in 0.1% serum results in the expected accumulation of cells with a G1 DNA 
content (Fig. 1A). Re-stimulation with 10% serum results in cell cycle re-entry and 
DNA replication after 6-24 h culture. However, if Nutlin-3, a pharmacological 
inhibitor of the Hdm2 : p53 interaction [6] is added to the medium, G1 exit is blocked, 
confirming that these cells remain dependent on Hdm2 function.  
 
Serum starvation resulted in reduced Hdm2 protein levels compared to asynchronous, 
cells (Fig. 1B). Following serum re-stimulation, Hdm2 protein levels increased 
rapidly, within 30 min. of stimulation. Hdm2 detectable by the 2A9 monoclonal 
antibody (upper panel) continued to increase from 30 min up to a peak at 
approximately 3 h post-stimulation, after which it declined. This induction was 
confirmed using an antibody to a different epitope on Hdm2 (2A10).  In comparison 
to Hdm2, p21WAF-1 showed a more modest, and delayed, increase, with an 
approximately 2 fold up-regulation observable at 3 h post-stimulation. During this 
time course, overall levels of p53 remained essentially unchanged, potentially 
reflecting a combined effect of higher rates of synthesis with increased Hdm2-
dependent degradation.. 
 
3.2. Effects of serum-stimulation on hdm2 mRNA synthesis, nuclear export and 
translation. 
 
We next investigated whether the elevation of Hdm2 protein levels following serum 
stimulation involves a selective increase in hdm2-mRNA expression, using previously 
validated reverse transcription - qPCR assays which are specific to each hdm2 
transcript [16]. 1 h following serum stimulation there was no significant increase in 
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either hdm2-P1 or hdm2-P2 transcript levels in the cells, compared to the gapdh 
housekeeping mRNA (Fig. 2Ai). A qPCR assay directed towards the hdm2 coding 
sequence (CDS) also showed no change. This contrasted to when p53-dependent 
transcription in the cells was activated by Nutlin-3 (Fig. 2Aii), which caused an 11.7 
fold increase in hdm2 P2-transcript levels, and a corresponding 5.2 fold increase in 
total hdm2 CDS mRNA. 
 
We therefore performed sub-cellular fractionation analysis [16] to determine whether 
hdm2 mRNA is regulated at the post-transcriptional level following serum-stimulation 
(Fig. 2B). Within the 1 h timescale examined, there was no significant increase in the 
levels of hdm2 mRNA transcripts in the cytoplasmic fraction, indicating that serum 
stimulation does not lead to a selective enhancement of nuclear export of hdm2 
mRNA. Furthermore, when cytoplasmic extracts were subjected to sucrose density 
centrifugation, there was no serum-induced increase in hdm2 transcripts in the high 
molecular weight-polyribosome associated fraction, indicating that rates of hdm2 
translation are not selectively increased. 
 
3.3. Role of PI3 kinase - Akt-dependent Hdm2 protein stabilisation 
 
Fig. 3A shows that when proteosome-dependent degradation of Hdm2 is inhibited 
using MG132, Hdm2 protein accumulates as least as rapidly as is does following 
serum stimulation. Therefore Hdm2 protein is being actively synthesised in serum 
starved cells, and serum-induced signalling pathways could theoretically cause the 
observed increase in Hdm2 protein solely by reducing the rates of its degradation.  
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Treatment of MRC-5 hTERT cells with the PI3 kinase inhibitor, LY294002, blocked 
serum-induced activation of Akt (Fig. 3B) and also effectively blocked the serum 
induced increase in Hdm2 protein levels (Fig. 3B, compare lanes 3 and 4), 
demonstrating that the increase in Hdm2 protein is PI3 kinase dependent. Inhibition of 
PI3 kinase did not block the increase in Hdm2 protein caused by the MG132 
proteosome inhibitor alone (not shown), and, more importantly, Hdm2 protein was 
still upregulated in the presence of 10% serum and MG132 when LY294002 was 
added. Therefore LY294002 does not prevent Hdm2 protein synthesis in either the 
absence or presence of serum growth factors. Together these data suggest that the 
primary mechanism underlying the selective up-regulation of Hdm2 protein levels 
following serum stimulation of human fibroblasts is the well documented PI3 kinase – 
Akt dependent enhancement of Hdm2 protein stability, with no evidence of any 
selective increase in hdm2 mRNA synthesis, export or translation. This conclusion is 
supported by the analysis of Hdm2 protein stability in these cells (Fig. 3C). Following 
blockade of protein synthesis by cyclohexamide, Hdm2 protein falls to undetectable 
levels within 45 min in starved cells, whereas following serum stimulation Hdm2 is 
still clearly detectable at this time point. In the presence of serum and LY294002, 
Hdm2 is degraded more rapidly than in serum starved cells.  
 
3.4. MEK activity is required for optimal Hdm2 protein synthesis 
 
The previous experiments do not exclude a role for Ras-Raf-MEK-ERK signalling in 
optimal growth factor-induced Hdm2 expression, and therefore we investigated the 
role of this pathway. We found that, when the pharmacological MEK inhibitor U0126 
is added at the time of serum re-stimulation, ERK activation is blocked and a modest, 
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but reproducible, decrease in Hdm2 protein levels is observed (Fig. 4A). U0126 also 
causes a  small reduction in the Hdm2 protein levels induced by MG132, indicating a 
decrease in the rate of protein synthesis following MEK inhibition. This reduction in 
Hdm2 synthesis did not occur due to any specific effects on hdm2 mRNA synthesis or 
translation, as U0126 did not cause any decrease in hdm2 mRNA associated with 
polyribosomes relative to gapdh mRNA (Fig. 4B). However, when the amounts of 
RNA yielded from the different fractions were analysed, we observed a reduction in 
the proportion of the total cytoplasmic RNA that was associated with polyribosomes 
from 42% in serum re-stimulated cells to 24% with U0126 treatment. This represents 
a 42% decrease in global translation rates following MEK inhibition, and would 
account for the U0126-induced reduction in Hdm2 protein levels compared to the 
majority of other, more stable, cellular proteins. 
 
4. Discussion 
 
Along with p53, Hdm2 lies at a point of integration of a huge range of both intra- and 
extra-cellular stimuli, the fine balance of the activities of these two proteins playing a 
key role in cell proliferation and survival [1]. Hdm2 itself can be regulated at multiple 
points, both pre-and post-translational, even in response to a single type of stimulus 
and it is often difficult to establish, in any given situation, which mechanisms are 
primarily responsible for any observed changes in cellular Hdm2 activity. Here we 
have shown that, when phenotypically normal human fibroblast cells are stimulated to 
proliferate by serum growth factors, the rapid increase in Hdm2 protein levels is 
primarily dependent upon activation of the PI3 kinase – Akt/PKB signalling pathway, 
and resultant reduced rates of proteosome-dependent degradation of the Hdm2 
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protein, which is known to involve the direct phosphorylation of Hdm2 by Akt/PKB 
[18-20].  
 
A second major growth factor-induced kinase cascade, Ras-Raf-MEK-ERK is, as has 
previously been shown in different experimental systems by a number of groups 
including our own [13,14,16], also required for optimal rates of Hdm2 synthesis in 
these cells. However, this is not due to any selective regulation of hdm2 mRNA 
expression or translation, but rather reflects the known requirement for Ras-Raf-
MEK-ERK signalling for the global increase in mRNA translation and protein 
synthesis in response to serum growth factors [23,24]. It is interesting to consider why 
the previously described mechanisms of specific MEK-dependent regulation of Hdm2 
synthesis are not observed in this system. We have shown previously that incubation 
of breast cancer epithelial cells with U0126 for 7-24 h results in the selective 
inhibition of nuclear export of hdm2 mRNA [16], however serum stimulation of 
fibroblasts has no specific effect on hdm2 mRNA export. Potentially therefore, hdm2 
regulation at this level occurs in some cell types, and not others, or alternatively the 
effect may only be observed following prolonged inhibition of MEK activity. Other 
studies have shown murine mdm2 to be induced by growth factors receptors and Ras-
Raf-MEK-ERK signalling, through immediate early type transcriptional activation of 
the P2 promoter [13,14], Here we have shown that this does not occur following 
serum stimulation of human fibroblasts. Whilst we have previously confirmed that 
human Hdm2-P2 transcription expression is positively influenced by MEK activity in 
cancer cells [16], we have noted differences in the transcription factor binding 
elements in the human and murine P2-promoters which could result in the human 
promoter being less responsive to this pathway [15]. Alternatively, it may be relevant 
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that previous reports [13,14] only directly demonstrated MEK-dependent regulation 
of P2 transcription when components of the signalling pathway were either artificially 
over-expressed, or contained constitutive activating mutations, and therefore, over-
stimulation of the growth factor receptor-Ras-Raf-MEK-ERK pathway may be  
required for Hdm2 P2 promoter activation to occur. 
 
In the broader perspective, Hdm2 over-expression is associated with a wide number 
of malignancies and Hdm2 is a target for a new class of small molecules with 
potential a cancer therapeutics [6]. This study on the normal pathways of Hdm2 
regulation highlights some of the multiplicity of mechanisms whereby dysregulated 
intracellular signalling pathways might result in Hdm2 over-expression in tumours. 
 
Acknowledgements 
We are grateful to Professor Bert Vogelstein for making available the pCMV-mdm2 
expression vector. This work was supported by the Association for International 
Cancer Research (#04-422). 
 
References 
[1] Vogelstein, B., Lane, D. and Levine, A.J. (2000) Surfing the p53 network. 
Nature 408, 307-10. 
[2] Momand, J., Wu, H.H. and Dasgupta, G. (2000) MDM2--master regulator of 
the p53 tumor suppressor protein. Gene 242, 15-29. 
[3] Blaydes, J.P. and Wynford-Thomas, D. (1998) The proliferation of normal 
human fibroblasts is dependent upon negative regulation of p53 function by 
mdm2. Oncogene 16, 3317-22. 
  Regulation of Hdm2 expression 
- 12 - 
[4] Jones, S.N., Roe, A.E., Donehower, L.A. and Bradley, A. (1995) Rescue of 
embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378, 
206-8. 
[5] Montes de Oca Luna, R., Wagner, D.S. and Lozano, G. (1995) Rescue of early 
embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 
203-6. 
[6] Vassilev, L.T. et al. (2004) In vivo activation of the p53 pathway by small-
molecule antagonists of MDM2. Science 303, 844-8. 
[7] Juven, T., Barak, Y., Zauberman, A., George, D.L. and Oren, M. (1993) Wild 
type p53 can mediate sequence-specific transactivation of an internal  
promoter within the mdm2 gene. Oncogene 8, 3411-6. 
[8] Zauberman, A., Flusberg, D., Barak, Y. and Oren, M. (1995) A functional 
p53-responsive intronic promoter is contained within the human  mdm2 gene. 
Nucleic Acids Res. 23, 2584-92. 
[9] Mendrysa, S.M., McElwee, M.K., Michalowski, J., O'Leary, K.A., Young, 
K.M. and Perry, M.E. (2003) mdm2 Is critical for inhibition of p53 during 
lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 23, 462-
72. 
[10] Brown, C.Y., Mize, G.J., Pineda, M., George, D.L. and Morris, D.R. (1999) 
Role of two upstream open reading frames in the translational control of 
oncogene mdm2. Oncogene 18, 5631-7. 
[11] Mosner, J. and Deppert, W. (1994) p53 and mdm2 are expressed 
independently during cellular proliferation. Oncogene 9, 3321-8. 
  Regulation of Hdm2 expression 
- 13 - 
[12] Shaulian, E., Resnitzky, D., Shifman, O., Blandino, G., Amsterdam, A., 
Yayon, A. and Oren, M. (1997) Induction of Mdm2 and enhancement of cell 
survival by bFGF. Oncogene 15, 2717-25. 
[13] Fambrough, D., McClure, K., Kazlauskas, A. and Lander, E.S. (1999) Diverse 
signaling pathways activated by growth factor receptors induce broadly 
overlapping, rather than independent, sets of genes. Cell 97, 727-41. 
[14] Ries, S. et al. (2000) Opposing effects of Ras on p53: transcriptional activation 
of mdm2 and induction of p19ARF. Cell 103, 321-330. 
[15] Phelps, M., Darley, M., Primrose, J.N. and Blaydes, J.P. (2003) p53-
independent activation of the hdm2-P2 promoter through multiple 
transcription factor response elements results in elevated hdm2 expression in 
estrogen receptor alpha positive breast cancer cells. Cancer Res 63, 2616-
2623. 
[16] Phelps, M., Phillips, A., Darley, M. and Blaydes, J.P. (2005) MEK-ERK 
signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA 
export to the cytoplasm. J Biol Chem 280, 16651-8. 
[17] Stott, F.J. et al. (1998) The alternative product from the human CDKN2A 
locus, p14(ARF), participates in a regulatory feedback loop with p53 and 
MDM2. EMBO J. 17, 5001-14. 
[18] Mayo, L.D. and Donner, D.B. (2001) A phosphatidylinositol 3-kinase/Akt 
pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. 
Proc Natl Acad Sci U S A 98, 11598-11603. 
[19] Ashcroft, M., Ludwig, R.L., Woods, D.B., Copeland, T.D., Weber, H.O., 
MacRae, E.J. and Vousden, K.H. (2002) Phosphorylation of HDM2 by Akt. 
Oncogene 21, 1955-62. 
  Regulation of Hdm2 expression 
- 14 - 
[20] Feng, J., Tamaskovic, R., Yang, Z., Brazil, D.P., Merlo, A., Hess, D. and 
Hemmings, B.A. (2004) Stabilization of Mdm2 via decreased ubiquitination is 
mediated by protein kinase B/Akt-dependent phosphorylation. J Biol Chem 
279, 35510-7. 
[21] McSharry, B.P., Jones, C.J., Skinner, J.W., Kipling, D. and Wilkinson, G.W. 
(2001) Human telomerase reverse transcriptase-immortalized MRC-5 and 
HCA2 human fibroblasts are fully permissive for human cytomegalovirus. J 
Gen Virol 82, 855-63. 
[22] Chen, J., Marechal, V. and Levine, A.J. (1993) Mapping of the p53 and mdm-
2 interaction domains. Mol Cell Biol 13, 4107-14. 
[23] Zong, Q., Schummer, M., Hood, L. and Morris, D.R. (1999) Messenger RNA 
translation state: the second dimension of high-throughput expression 
screening. Proc Natl Acad Sci U S A 96, 10632-6. 
[24] Wang, X., Flynn, A., Waskiewicz, A.J., Webb, B.L., Vries, R.G., Baines, I.A., 
Cooper, J.A. and Proud, C.G. (1998) The phosphorylation of eukaryotic 
initiation factor eIF4E in response to phorbol esters, cell stresses, and 
cytokines is mediated by distinct MAP kinase pathways. J Biol Chem 273, 
9373-7. 
 
 
Figure Legends 
 
Fig. 1 Role of Hdm2 in serum-stimulated cell-cycle re-entry. MRC-5 hTERT cells 
were cultured for 24 h in DMEM / 0.1% FCS, then refed with DMEM / 10% FCS 
before analysis at the indicated time points. (A) Cellular DNA content was 
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determined by flow cytometric analysis of propidium iodide stained cells. Nutlin–3 (5 
µM) was added to the DMEM / 10% FCS where indicated. (B) Hdm2 was detected by 
western blotting using both 2A9 (top panel) and 2A10 monoclonal antibodies, which 
recognise different epitopes. Exposure times for the individual blots were varied in 
order to best observe the changes in Hdm2 protein levels. 
 
Fig. 2 Effect of serum stimulation on hdm2 mRNA expression, localisation and 
translation. Hdm2 mRNA in MRC-5 hTERT cells was analysed using RT - qPCR. 
hdm2-P1 (white bars) and hdm2-P2 (grey bars) transcripts, as well as hdm2-CDS 
containing mRNA (black bars). (Ai) Cells were starved and refed as in Fig. 1A. Total 
RNA from starved (0 h) and refed (1 h) cells was analysed. Data is mean + S.E.M. for 
5 individual experiments.  (Aii) Asynchronous cells growing in DMEM / 10% FCS 
were exposed to 5 µM Nutlin-3 (N) or carrier control (C) for 3 h before total RNA 
and protein was extracted for RT – qPCR and western blot analysis. (B) Cells were 
cultured as in Ai. Prior to mRNA extraction, cells were fractionated by low salt 
hypotonic lysis to produce a nuclear pellet, and soluble cytoplasmic fraction (S). The 
cytoplasmic fraction was further fractionated to isolate polyribosome associated 
mRNA (PA). Fractionations were validated using semi-quantitative PCR for small 
cytoplasmic RNA Y4 and gapdh. Two different amounts (3 fold dilution) of input 
cDNA were used for each sample. The graphs show hdm2 levels at 1 h as a 
percentage of those in starved cells. n=2. 
 
Fig. 3 PI3 kinase dependent Hdm2 stabilisation is sufficient to account for the serum-
induced Hdm2 induction. (A) Cells were cultured in DMEM / 0.1% FCS for 24 h then 
cells were refed with medium containing 10% serum and / or 50 µM MG132. (B) 
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Cells were cultured in DMEM / 0.1% FCS for 24 h then refed using medium 
containing the indicated combinations of 10% serum, 50 µM MG132 and 10 µM 
LY294002. Akt activation by phosphorylation at serine 473 was determined following 
45 min. exposure of cells to 10% serum and either 10 µM LY294002 or carrier 
control. (C) Cells in 100 mm culture dishes were transfected for 24 h with 8 µg of the 
pCMV-mdm2 expression vector (encoding full length human Hdm2), before being 
cultured in DMEM / 0.1% FCS for 24 h. Cells were refed with medium containing the 
indicated combination of serum and 10 µM LY294002 or carrier control for 45 min. 
before 100 µg/ml cycloheximide (CHX) was added to the medium to block new 
protein synthesis. Cells were lysed at the time points indicated after cyclohexamide 
addition. 
 
Fig. 4 MEK activity is required for optimal Hdm2 synthesis following serum re-
stimulation. Cells were cultured in DMEM / 0.1% FCS for 24 h then treated as 
indicated (A) Cells were refed with medium containing 10% serum and / or 50 µM 
MG132 or 25 µM U0126 before blotting for Hdm2. ERK phosphorylation was 
determined at 45 min post serum re-stimulation. (B) hdm2 coding sequence 
containing mRNA was quantified in either total (TOT) or polyribosome associated 
(PA) RNA fractions from cells 45 min after refeeding. Levels are shown relative to 
gapdh  mRNA expression. Open bars = no serum, grey bars = 10% serum, black bars 
= 10% serum + 25 µM U0126. 
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Fig. 1 
 
 
 
Fig. 2 
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Fig. 3 
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Fig. 4 
 
 
